A number of firms have modified their ratings and price targets on shares of Dynavax Technologies Corporation (NASDAQ: DVAX) recently:

  • 8/4/2017 – Dynavax Technologies Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 7/31/2017 – Dynavax Technologies Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Dynavax Technologies Corporation was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating. They now have a $26.00 price target on the stock, up previously from $7.00.
  • 7/31/2017 – Dynavax Technologies Corporation was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $27.00 price target on the stock, up previously from $6.00.
  • 7/27/2017 – Dynavax Technologies Corporation had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $45.00 price target on the stock.
  • 7/27/2017 – Dynavax Technologies Corporation had its “outperform” rating reaffirmed by analysts at William Blair.
  • 7/26/2017 – Dynavax Technologies Corporation was given a new $7.00 price target on by analysts at Royal Bank Of Canada. They now have a “hold” rating on the stock.
  • 7/11/2017 – Dynavax Technologies Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “
  • 7/10/2017 – Dynavax Technologies Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 1.36% during mid-day trading on Tuesday, reaching $18.65. 4,317,862 shares of the company’s stock were exchanged. The company has a 50-day moving average of $10.50 and a 200-day moving average of $6.66. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $19.60. The stock’s market cap is $926.91 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 101.98%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. During the same quarter last year, the company posted ($0.75) earnings per share. Equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.18) earnings per share for the current year.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.